LON:NBB

Norman Broadbent Final Earnings Results & Report

GBX 227 0.00 (0.00%)
As of 11/20/2026

Norman Broadbent reported Final earnings on April 2, 2025. The company reported EPS of -GBX 0.15.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Norman Broadbent EPS Results

Actual EPS
-GBX 0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Norman Broadbent Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Norman Broadbent Final Earnings FAQ

Norman Broadbent (LON:NBB) reported earnings of -GBX 0.15 per share for Final. The report was announced on Wednesday, April 2, 2025.

Norman Broadbent Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Norman Broadbent Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Norman Broadbent? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Norman Broadbent and other key companies, straight to your email.

About Norman Broadbent

Norman Broadbent (LON:NBB) is a professional services firm focused on executive search, senior interim management solutions and bespoke leadership advisory services working across the UK and internationally. Established as the first UK-headquartered search firm in 1979, the firm has a 40+ year track record of shaping leadership across industries including Consumer, Financial Services, Industrials, Life Sciences, Investor and TMT.

View Norman Broadbent Profile